ArticleJournal of translational medicine2025

Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax.

Ilenia Valentino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.